Alnylam said this week that it has co-exclusively licensed from Stanford University the therapeutic rights to a patent application covering RNAi-mediated inhibition of gene expression in mammals, as well as related technology.
Alnylam said this week that it has co-exclusively licensed from Stanford University the therapeutic rights to a patent application covering RNAi-mediated inhibition of gene expression in mammals, as well as related technology.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.